Back to search

Article

Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine

2022-05-27

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Variant-adaptated vaccines against coronavirus disease 2019 (COVID-19) as boosters are needed to increase a broader protection against SARS CoV-2 variants. New adjuvanted recombinant protein vaccines as heterologous boosters could maximize the response. <h4>Methods</h4> In this randomized, single-blinded, multicenter trial, adults who had received two doses of Pfizer-BioNTech...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c8d1997c-2e8e-54a7-a980-b1e779af6844
DOI
10.1101/2022.05.25.22274904
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster VaccineDOI 10.1101/2022.05.25.22274904
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccinesSemantic proximity
Humoral Immune Response Against Sars-Cov-2 Variants (Omicron Ba.1, Ba.4/5, Beta and Delta) of Phh-1v Booster Vaccine in Subjects Previously Vaccinated with a Mrna Vaccine. Results of a Randomised Controlled Trial Up to 6 MonthsSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim reportSemantic proximity
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccinesSemantic proximity
Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccineSemantic proximity
Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity
Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity
The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary SeriesSemantic proximity
Select a neighboring publication to make it the new centre.